Tags

Type your tag names separated by a space and hit enter

Influence of blood pressure on the effectiveness of a fixed-dose combination of isosorbide dinitrate and hydralazine in the African-American Heart Failure Trial.
J Am Coll Cardiol. 2007 Jan 02; 49(1):32-9.JACC

Abstract

OBJECTIVES

This study sought to assess the effect of baseline systolic blood pressure (SBP) and changes in SBP on the effectiveness of treatment with fixed-dose combination of isosorbide dinitrate and hydralazine (FDC I/H) in patients with heart failure (HF).

BACKGROUND

Low SBP is a risk factor for adverse outcomes in patients with HF. However, FDC I/H lowered SBP in the A-HeFT (African-American Heart Failure Trial) and yet prolonged survival. Whether blood pressure (BP) lowering is critical to the efficacy of FDC I/H and whether a low BP limits its effectiveness is unclear.

METHODS

The effects of FDC I/H on SBP and on mortality and hospitalization were compared in patients with a low or high baseline SBP using multivariable Cox regression models. The interaction between the effect of treatment and baseline SBP was examined.

RESULTS

Mean +/- SD baseline SBP in all of the patients was 126 +/- 18 mm Hg. Patients with baseline SBP equal to or below the median (126 mm Hg) had features of more severe HF. Baseline SBP equal to or below the median was an independent risk factor for death (hazard ratio [HR] 2.09; 95% confidence interval [CI] 1.02 to 4.29) or first hospitalization for HF (HR 1.66; 95% CI 1.18 to 2.34). The FDC I/H treatment reduced BP in patients with SBP above the median but not in patients with SBP below 126 mm Hg. The FDC I/H treatment was associated with a similar decrease in mortality or hospitalization for HF in patients with SBP below the median and above the median. The effects of FDC I/H on mortality alone were also similar.

CONCLUSIONS

In A-HeFT, patients with lower SBP had a greater risk but a similar relative benefit from the use of FDC I/H as those with higher SBP. The FDC I/H treatment did not reduce SBP in patients with low SBP. An asymptomatic low SBP should not be considered a contraindication to use of FDC I/H in patients with HF.

Authors+Show Affiliations

VA Medical Center, Minneapolis, Minnesota, USA. anand001@umn.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17207719

Citation

Anand, Inder S., et al. "Influence of Blood Pressure On the Effectiveness of a Fixed-dose Combination of Isosorbide Dinitrate and Hydralazine in the African-American Heart Failure Trial." Journal of the American College of Cardiology, vol. 49, no. 1, 2007, pp. 32-9.
Anand IS, Tam SW, Rector TS, et al. Influence of blood pressure on the effectiveness of a fixed-dose combination of isosorbide dinitrate and hydralazine in the African-American Heart Failure Trial. J Am Coll Cardiol. 2007;49(1):32-9.
Anand, I. S., Tam, S. W., Rector, T. S., Taylor, A. L., Sabolinski, M. L., Archambault, W. T., Adams, K. F., Olukotun, A. Y., Worcel, M., & Cohn, J. N. (2007). Influence of blood pressure on the effectiveness of a fixed-dose combination of isosorbide dinitrate and hydralazine in the African-American Heart Failure Trial. Journal of the American College of Cardiology, 49(1), 32-9.
Anand IS, et al. Influence of Blood Pressure On the Effectiveness of a Fixed-dose Combination of Isosorbide Dinitrate and Hydralazine in the African-American Heart Failure Trial. J Am Coll Cardiol. 2007 Jan 2;49(1):32-9. PubMed PMID: 17207719.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Influence of blood pressure on the effectiveness of a fixed-dose combination of isosorbide dinitrate and hydralazine in the African-American Heart Failure Trial. AU - Anand,Inder S, AU - Tam,S William, AU - Rector,Thomas S, AU - Taylor,Anne L, AU - Sabolinski,Michael L, AU - Archambault,W Tad, AU - Adams,Kirkwood F, AU - Olukotun,Adeoye Y, AU - Worcel,Manuel, AU - Cohn,Jay N, Y1 - 2006/12/14/ PY - 2006/03/03/received PY - 2006/04/12/revised PY - 2006/04/17/accepted PY - 2007/1/9/pubmed PY - 2007/1/31/medline PY - 2007/1/9/entrez SP - 32 EP - 9 JF - Journal of the American College of Cardiology JO - J Am Coll Cardiol VL - 49 IS - 1 N2 - OBJECTIVES: This study sought to assess the effect of baseline systolic blood pressure (SBP) and changes in SBP on the effectiveness of treatment with fixed-dose combination of isosorbide dinitrate and hydralazine (FDC I/H) in patients with heart failure (HF). BACKGROUND: Low SBP is a risk factor for adverse outcomes in patients with HF. However, FDC I/H lowered SBP in the A-HeFT (African-American Heart Failure Trial) and yet prolonged survival. Whether blood pressure (BP) lowering is critical to the efficacy of FDC I/H and whether a low BP limits its effectiveness is unclear. METHODS: The effects of FDC I/H on SBP and on mortality and hospitalization were compared in patients with a low or high baseline SBP using multivariable Cox regression models. The interaction between the effect of treatment and baseline SBP was examined. RESULTS: Mean +/- SD baseline SBP in all of the patients was 126 +/- 18 mm Hg. Patients with baseline SBP equal to or below the median (126 mm Hg) had features of more severe HF. Baseline SBP equal to or below the median was an independent risk factor for death (hazard ratio [HR] 2.09; 95% confidence interval [CI] 1.02 to 4.29) or first hospitalization for HF (HR 1.66; 95% CI 1.18 to 2.34). The FDC I/H treatment reduced BP in patients with SBP above the median but not in patients with SBP below 126 mm Hg. The FDC I/H treatment was associated with a similar decrease in mortality or hospitalization for HF in patients with SBP below the median and above the median. The effects of FDC I/H on mortality alone were also similar. CONCLUSIONS: In A-HeFT, patients with lower SBP had a greater risk but a similar relative benefit from the use of FDC I/H as those with higher SBP. The FDC I/H treatment did not reduce SBP in patients with low SBP. An asymptomatic low SBP should not be considered a contraindication to use of FDC I/H in patients with HF. SN - 1558-3597 UR - https://www.unboundmedicine.com/medline/citation/17207719/Influence_of_blood_pressure_on_the_effectiveness_of_a_fixed_dose_combination_of_isosorbide_dinitrate_and_hydralazine_in_the_African_American_Heart_Failure_Trial_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0735-1097(06)02579-4 DB - PRIME DP - Unbound Medicine ER -